

Clinical trials of cangrelor

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
cangrelor up front vs clopidogrel up front			
CHAMPION-PCI , 2009 [NCT00305162] n=4367/4355 follow-up: 48 h	cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) versus clopidogrel up front (clopidogrel followed by placebo)	high risk patients requiring PCI	Parallel groups double blind 14 countries
cangrelor up front vs delayed clopidogrel			
CHAMPION-PLATFORM , 2009 [NCT00385138] n=2693/2669 follow-up: 48 h	cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) versus delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel)	patients with acute coronary syndrome undergoing percutaneous coronary intervention	Parallel groups double blind 18 countries

More details and results :

- New P2Y12 Inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q455>

References

CHAMPION-PCI, 2009:

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009 Dec 10;361:2318-29 [19915221]

CHAMPION-PLATFORM, 2009:

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med 2009 Nov 15;: [19915222]

2 CABG surgery

Trial	Treatments	Patients	Trials design and methods
cangrelor vs placebo			
Bridge <i>ongoing</i> [NCT00767507] n=NA follow-up:	Cangrelor versus placebo	patients undergoing surgery	Parallel groups double blind

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

References

Bridge, :

ongoing trial NCT00767507

3 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
cangrelor vs clopidogrel			
CHAMPION PHOENIX , 2013 [NCT01156571] n=5472/5470 follow-up: 48 hours	bolus and infusion of cangrelor followed by 600mg clopidogrel immediately post-infusion versus loading dose of 600 mg or 300 mg of clopidogrel	patients undergoing PCI for stable angina or for acute coronary syndromes, including ST-elevation MI	Parallel groups double-blind
cangrelor up front vs clopidogrel up front			
CHAMPION-PCI , 2009 [NCT00305162] n=4367/4355 follow-up: 48 h	cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) versus clopidogrel up front (clopidogrel followed by placebo)	high risk patients requiring PCI	Parallel groups double blind 14 countries
cangrelor up front vs delayed clopidogrel			
CHAMPION-PLATFORM , 2009 [NCT00385138] n=2693/2669 follow-up: 48 h	cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) versus delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel)	patients with acute coronary syndrome undergoing percutaneous coronary intervention	Parallel groups double blind 18 countries

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- pre treatment for PCI for percutaneous coronary intervention in stable and unstable ACS at <http://www.trialresultscenter.org/go-Q160>

References

CHAMPION PHOENIX, 2013:

Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012;163:768-776.e2 [22607853]

Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsk P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Gnreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013 Mar 10;: [23473369] 10.1056/NEJMoa1300815

CHAMPION-PCI, 2009:

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009 Dec 10;361:2318-29 [19915221]

CHAMPION-PLATFORM, 2009:

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med 2009 Nov 15;: [19915222]

Entry terms: AR C69931MX, AR-C69931MX,